Drug Search Results
More Filters [+]

Mazindol

Alternative Names: mazindol, mazanor, Quilience, sanorex
Latest Update: 2024-10-21
Latest Update Note: News Article

Product Description

Mechanisms of Action: DRI Inhibitor,NRI Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Canada | Chile | Dominican Republic | Ecuador | Ireland | Korea | Mexico | New Zealand | Peru | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: NLS Pharmaceutics
Company Location: STANS V8 CH-6370
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mazindol

Countries in Clinic: United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Cataplexy|Narcolepsy

Phase 2: Disorders of Excessive Somnolence

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AMAZE

P3

Not yet recruiting

Narcolepsy|Cataplexy

2025-07-30

90%

NLS-1022

P2

Completed

Cataplexy|Narcolepsy

2023-01-19

32%

NLS-1021

P2

Completed

Cataplexy|Narcolepsy|Disorders of Excessive Somnolence

2022-06-30

32%

Recent News Events